Epigenetic regulation and colorectal cancer

Diseases of the Colon and Rectum

Volumn 55, Issue 1, 2012, Pages 96-104

  Matsubara, Nagahide ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Epigenetic alteration; Histone modification; Promoter methylation

Indexed keywords

AZACITIDINE; BIOLOGICAL MARKER; DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; MG 98; TRANSCRIPTION FACTOR; VALPROIC ACID;

ADENOMATOUS POLYP; ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; CPG ISLAND; DIAGNOSTIC VALUE; DNA METHYLATION; DRUG EFFICACY; EPIGENETICS; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC REGULATION; HUMAN; KIDNEY CANCER; MALIGNANT NEOPLASTIC DISEASE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PROGNOSIS; PROMOTER REGION; PROTEIN MODIFICATION; RISK ASSESSMENT; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; GERM-LINE MUTATION; HISTONES; HUMANS; INHERITANCE PATTERNS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856350708     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e318233a1ef     Document Type: Article

References (79)

1. Jubb AM, Quirke P, Oates AJ. DNA methylation, a biomarker for colorectal cancer: implications for screening and pathological utility. Ann N Y Acad Sci. 2003;983:251-267. (Pubitemid 36399338)
2. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319: 525-532.
3. Holliday R. DNA methylation and epigenetic defects in carcinogenesis. Mutat Res. 1987;181:215-217. (Pubitemid 18050849)
4. Riggs AD, Jones PA. 5-methylcytosine, gene regulation, and cancer. Adv Cancer Res. 1983;40:1-30.
5. Iino H, Simms L, Young J, et al. DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut. 2000;47: 37-42. (Pubitemid 30430409)
6. Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol. 2007;13:3784-3791. (Pubitemid 47272303)
7. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57:808-811. (Pubitemid 27097998)
8. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870-6875. (Pubitemid 28278073)
9. Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 2003;190:125-133. (Pubitemid 36136010)
10. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143-153. (Pubitemid 38198742)
11. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113-130. (Pubitemid 44953403)
12. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ. 2006;174: 341-348. (Pubitemid 43235307)
13. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681-8686. (Pubitemid 29354851)
14. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301:89-92. (Pubitemid 13154475)
15. Wong JJ, Hawkins NJ, Ward RL. Colorectal cancer: a model for epigenetic tumorigenesis. Gut. 2007;56:140-148. (Pubitemid 46044900)
16. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science. 1985;228:187-190. (Pubitemid 15117274)
17. Bariol C, Suter C, Cheong K, et al. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol. 2003;162:1361-1371. (Pubitemid 36350680)
18. Ji W, Hernandez R, Zhang XY, et al. DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutat Res. 1997;379:33-41. (Pubitemid 27394232)
19. Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis. 2004;19:95-101. (Pubitemid 38239827)
20. Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol. 2007;20:711-721. (Pubitemid 46933450)
21. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A. 1993;90:11995-11999. (Pubitemid 24008767)
22. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A. 2002; 99:3740-3745. (Pubitemid 34252176)
23. Curradi M, Izzo A, Badaracco G, Landsberger N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol. 2002;22:3157-3173. (Pubitemid 34437474)
24. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/ p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995; 55:4525-4530.
25. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol. 1998;18:6457-6473. (Pubitemid 28500536)
26. Costello JF, Futscher BW, Tano K, Graunke DM, Pieper RO. Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem. 1994;269:17228-17237. (Pubitemid 24204047)
27. Young J, Biden KG, Simms LA, et al. HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc Natl Acad Sci U S A. 2001;98:265-270. (Pubitemid 32095898)
28. Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7:536-540. (Pubitemid 24308343)
29. Kawakami K, Ruszkiewicz A, Bennett G, et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer. 2006;94:593-598. (Pubitemid 43289765)
30. Nagasaka T, Goel A, Notohara K, et al. Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer. 2008; 122:2429-2436. (Pubitemid 351590474)
31. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23:29-39. (Pubitemid 38221595)
32. Kimura N, Nagasaka T, Murakami J, et al. Methylation profiles of genes utilizing newly developed CpG island methylation microarray on colorectal cancer patients. Nucleic Acids Res. 2005; 33:e46.
33. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation- specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826. (Pubitemid 26296693)
34. Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999;59: 2302-2306. (Pubitemid 29242272)
35. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997;25:2532-2534. (Pubitemid 27303718)
36. Tost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques. 2003;35:152-156. (Pubitemid 36828725)
37. Rashid A, Issa JP. CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology. 2004;127:1578-1588. (Pubitemid 39457781)
38. Ward RL, Cheong K, Ku SL, et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol. 2003;21:3729-3736. (Pubitemid 46606226)
39. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787-793. (Pubitemid 43980599)
40. Nagasaka T, Sasamoto H, Notohara K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol. 2004;22:4584-4594. (Pubitemid 41185126)
41. Boisvert-Adamo K, Aplin AE. B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. Oncogene. 2006;25:4848-4856. (Pubitemid 44201176)
42. Wynter CV, Walsh MD, Higuchi T, et al. Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut. 2004;53:573-580. (Pubitemid 38372984)
43. Oberst MD, Beberman SJ, Zhao L, et al. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation. BMC Cancer. 2008;8:189.
44. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol. 2003;27:65-81. (Pubitemid 36014900)
45. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated withDNAmethylation in serrated polyps and cancers of the colorectum. Gut. 2004;53:1137-1144. (Pubitemid 38961968)
46. Jass JR. Serrated adenoma of the colorectum and the DNAmethylator phenotype. Nat Clin Pract Oncol. 2005;2:398-405. (Pubitemid 43115008)
47. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int. 2000;50: 273-279. (Pubitemid 30441278)
48. Nagasaka T, Koi M, Kloor M, et al. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology. 2008;134:1950-1960, 1960.e1.
49. Ishii T, Notohara K, Umapathy A, et al. Tubular adenomas with minor villous changes show molecular features characteristic of tubulovillous adenomas. Am J Surg Pathol. 2011;35:212-220.
50. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846-856. (Pubitemid 44629896)
51. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125:315-326.
52. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39:232-236. (Pubitemid 46184355)
53. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39:157-158. (Pubitemid 46184343)
54. Chan TL, Yuen ST, Kong CK, et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet. 2006;38:1178-1183. (Pubitemid 44470364)
55. Yu J, Rhodes DR, Tomlins SA, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer research. 2007;67:10657-10663. (Pubitemid 350145890)
56. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074-1080. (Pubitemid 32758077)
57. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429: 457-463. (Pubitemid 38715140)
58. Rodriguez J, Munoz M, Vives L, et al. Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proc Natl Acad Sci U S A. 2008;105:19809-19814.
59. Huang Y, Greene E, Murray Stewart T, et al. Inhibition of lysinespecific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A. 2007;104:8023-8028. (Pubitemid 47185869)
60. Horsthemke B. Heritable germline epimutations in humans. Nat Genetics. 2007;39:573-576.
61. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet. 2004;36: 497-501. (Pubitemid 38620035)
62. Hitchins MP, Wong JJ, Suthers G, et al. Inheritance of a cancerassociated MLH1 germ-line epimutation. N Engl J Med. 2007; 356:697-705.
63. Chong S, Youngson NA, Whitelaw E. Heritable germline epimutation is not the same as transgenerational epigenetic inheritance. Nat Genetics. 2007;39:574-576.
64. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3 exons of TACSTD1. Nat Genet. 2009;41:112-117.
65. Constantinides PG, Jones PA, Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature. 1977;267:364-366. (Pubitemid 8119790)
66. Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discov. 2005;4:275-276. (Pubitemid 41130933)
67. Surbone A, Ford H Jr, Kelley JA, et al. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272). Cancer Res. 1990;50:1220-1225. (Pubitemid 20084015)
68. Plummer R, Vidal L, Griffin M, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res. 2009;15:3177-3183.
69. Amato RJ. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer. 2007;5:422-426. (Pubitemid 351219694)
70. Mongan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther. 2005;4:477-486. (Pubitemid 40443933)
71. Balch C, Montgomery JS, Paik HI, et al. New anti-cancer strategies: epigenetic therapies and biomarkers. Front Biosci. 2005; 10:1897-1931. (Pubitemid 40532955)
72. Nagasaka T, Tanaka N, CullingsHM,et al. Analysis of fecalDNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst. 2009;101:1244-1258.
73. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28:3380-3387.
74. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-5712.
75. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 2009;27:1130-1136.
76. Nagasaka T, Sharp GB, Notohara K, et al. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin Cancer Res. 2003;9:5306-5312. (Pubitemid 37413584)
77. Murakami J, Lee YJ, Kokeguchi S, et al. Depletion of O6-methylguanine- DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol Rep. 2007;17:1461-1467.
78. Benatti P, Gafa R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11:8332-8340. (Pubitemid 41746945)
79. Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003;63:5738-5744. (Pubitemid 37187470)